NTC's Phase II Study Shows Promising Outcomes for Innovative Drug to Treat Bacterial Conjunctivitis NTC announces positive findings from its Phase II MIRAKLE study, showcasing the effectiveness of NTC014 in treating bacterial conjunctivitis in adults.

NTC's Phase II Study Shows Promising Outcomes for Innovative Drug to Treat Bacterial Conjunctivitis #Italy #Milan #NTC014 #bacterial_conjunctivitis #Phase_II_Trial